Cargando…

Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification

BACKGROUND: Hepatitis C virus (HCV) is currently classified into 8 genotypes and 86 subtypes. The objective of this study was to characterize novel HCV subtypes and to investigate the impact of subtypes on treatment outcome. METHODS: Full-genome sequencing was performed on HCV plasma samples with &l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hedskog, Charlotte, Parhy, Bandita, Chang, Silvia, Zeuzem, Stefan, Moreno, Christophe, Shafran, Stephen D, Borgia, Sergio M, Asselah, Tarik, Alric, Laurent, Abergel, Armand, Chen, Jyh-Jou, Collier, Jane, Kapoor, Dharmesh, Hyland, Robert H, Simmonds, Peter, Mo, Hongmei, Svarovskaia, Evguenia S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440686/ https://www.ncbi.nlm.nih.gov/pubmed/30949527 http://dx.doi.org/10.1093/ofid/ofz076

Ejemplares similares

Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage
por: Hostager, Reilly, et al.
Publicado: (2019)

Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes
por: Chaturvedi, Nimisha, et al.
Publicado: (2019)

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies
por: Yao, Betty B., et al.
Publicado: (2020)

Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
por: Martin, Ross, et al.
Publicado: (2021)

The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment
por: Gane, Edward J., et al.
Publicado: (2017)

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
por: Pageaux, Georges-Philippe, et al.
Publicado: (2022)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
por: Asselah, Tarik, et al.
Publicado: (2015)

Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350
por: Mok, Hoyin, et al.
Publicado: (2012)

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
por: Asselah, Tarik, et al.
Publicado: (2016)

Accumulation of Intrahepatic TNF-α-Producing NKp44(+) NK Cells Correlates With Liver Fibrosis and Viral Load in Chronic HCV Infection
por: Nel, Isabelle, et al.
Publicado: (2016)

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
por: Shiffman, Mitchell L, et al.
Publicado: (2016)

IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C
por: Estrabaud, Emilie, et al.
Publicado: (2015)

Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
por: Meunier, Lucy, et al.
Publicado: (2022)

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study
por: Feng, Joy Y, et al.
Publicado: (2009)

Quantitative HBsAg: Not helpful to evaluate fibrosis in HBeAg-negative chronic hepatitis B patients
por: Loureiro, Dimitri, et al.
Publicado: (2019)

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
por: Brown, Ashley, et al.
Publicado: (2019)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

When the Benign Pneumatosis Intestinalis Becomes No Longer Benign: A Rare Case of Bowel Perforation in a Patient with Systemic Sclerosis
por: Guan, Jian, et al.
Publicado: (2018)

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
por: Mühlberger, Nikolai, et al.
Publicado: (2009)

Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach
por: Li, Wei, et al.
Publicado: (2020)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
por: Asselah, Tarik, et al.
Publicado: (2016)

Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens
por: Gish, Robert G, et al.
Publicado: (2022)

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort
por: Laurain, Anne, et al.
Publicado: (2019)

Impact of COVID-19 on global HCV elimination efforts
por: Blach, Sarah, et al.
Publicado: (2021)

Endpoints and New Options for Treatment of Chronic Hepatitis D
por: Lok, Anna S., et al.
Publicado: (2021)

Performance of Radiomics in Microvascular Invasion Risk Stratification and Prognostic Assessment in Hepatocellular Carcinoma: A Meta-Analysis
por: Bodard, Sylvain, et al.
Publicado: (2023)

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies
por: Grebely, Jason, et al.
Publicado: (2018)

COVID-19: Discovery, diagnostics and drug development
por: Asselah, Tarik, et al.
Publicado: (2021)

Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus
por: Usai, Carla, et al.
Publicado: (2022)

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)
por: Asselah, Tarik, et al.
Publicado: (2019)

506. Resistance Analyses from the Remdesivir Phase 3 REDPINE Study in Participants with Severely Reduced Kidney Function Who Were Hospitalized for COVID-19
por: Andreatta, Kristen, et al.
Publicado: (2023)

Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV
por: Mateo, Roberto, et al.
Publicado: (2023)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts
por: Mangia, Alessandra, et al.
Publicado: (2020)

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response
por: Asselah, Tarik, et al.
Publicado: (2017)

Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α(18)
por: Stross, Claudia, et al.
Publicado: (2016)

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
por: Garbuglia, Anna Rosa, et al.
Publicado: (2014)

A twist in the tail: SHAPE mapping of long-range interactions and structural rearrangements of RNA elements involved in HCV replication
por: Tuplin, Andrew, et al.
Publicado: (2012)

The correlation of HCV RNA and HCV core antigen in different genotypes of HCV
por: Xiang, Yu, et al.
Publicado: (2018)

miRNAs as Potential Biomarkers for Viral Hepatitis B and C
por: Loureiro, Dimitri, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e5c8jh801hgssr2j09a2shtbbs